The Council for International Organizations of Medical Sciences (CIOMS) is an international, non-governmental, non-profit organization established jointly by WHO and UNESCO in 1949. In 2009 CIOMS celebrated the 60th anniversary of its creation.
Through its membership, CIOMS is representative of a substantial proportion of the biomedical scientific community. In 2013, the membership of CIOMS included 49 international, national and associate member organizations, representing many of the biomedical disciplines, national academies of sciences and medical research councils. The main objectives of CIOMS are:
Read more: About Us
The CIOMS V Working Group (WG) met in a series of 8 formal meetings during the years 1997 to 2000. The printed version of their report” Current Challenges in Pharmacovigilance: Pragmatic Approaches” was published in 2001. The CIOMS WG V, through its report, advocated acceptance for a wide range of proposals concerning issues covering terminology and definitions, common every-day practices such as follow-up of individual adverse events, the rational scheduling and content of periodic safety update reports (PSURs), the role of Internet and quantification of population drug use.The completed report, intended as a handbook for pharmacovigilance departments and still offering many pragmatic solutions to a number of issues, has been in great demand. CIOMS has now decided to make the publication available free of charge to download on its website.
Click here to access the download page
A new CIOMS Working Group (WG) has been established to address issues related to the information exchange between stakeholders on vaccine safety. The formation of the new WG is linked to the activities of the Global Vaccine Safety Blueprint of WHO and its implementation plan, the Global Vaccine Safety Initiative (GVSI). It is a global strategic plan that aims at assisting low and middle income countries (LMIC) in their work with vaccine safety surveillance.
The importance of close collaboration between stakeholders is well recognized in vaccine pharmacovigilance activities, and guidance has been developed, in industrialized countries, for jointly planning these activities.
Read more: NEW! CIOMS Working Group on Vaccine Safety
The 1985 International Guiding Principles for Biomedical Research Involving Animals have been revised by an ad hoc committee appointed by the Council for International Organizations of Medical Sciences (CIOMS) and the International Council for Laboratory Animal Science (ICLAS).
The revised International Guiding Principles for Biomedical Research Involving Animals reflect current best practices and standards of care in laboratory animal medicine and science and provide a touchstone or framework of responsibility and oversight to ensure the appropriate use of animals. They also may serve as a benchmark for advancing international collaboration in biomedical sciences.
It is hoped that international organizations and governmental agencies will adopt these revised International Guiding Principles for Biomedical Research Involving Animals and that they will encourage use by the scientific community worldwide.
click here to download document
The Council for International Organizations of Medical Sciences (CIOMS) is happy to announce the above joint publication between the World Health Organization (WHO), CIOMS and one of its new members, the International Union of Basic and Clinical Pharmacology (IUPHAR).
The report is an updated and extended version of a recent publication in Basic and Clinical Pharmacology and Toxicology (BCPT) and includes new chapters of special relevance to global health. CIOMS welcomes IUPHAR as a member.
Read more: New publication: The Role of Clinical Pharmacology in Health Care, Teaching and Research
On Tuesday, 27 November 2012, CIOMS held the 79th meeting of its Executive Committee (EC). The EC endorsed the general ambition to identify new issues of major relevance for the medical community where there is a need for review and global adoption of common principles and standards and to increase the interaction with member organizations and involvement of members of the EC in the activities of CIOMS, and to promote the work of CIOMS.
The Secretary-General presented a summary of the most important events and achievements over the year.
The programme for 2013 was also presented within the area of Drug Development and Use.
Read more: CIOMS Executive Commitee Meeting: 79th Session in Salle G, WHO Headquarters, Geneva, Switzerland
At its 78th Executive Committee Meeting in November 2011, CIOMS decided to initiate a review procedure of its Guidelines on Ethics in Biomedical Research published in 2002. The Guidelines are globally distributed and widely used.
Read more: First meeting of the new CIOMS Working Group on research ethics in Geneva
CIOMS Working Group IX was created in April 2010 based on suggestions from a number of drug regulatory authorities and pharmaceutical companies. The overall objective of the efforts of this Working Group is to consolidate concepts of risk management tools and propose their application in order to harmonize views and globally protect public health, and to positively impact prescriber-patient interactions.
Read more: CIOMS Working Group IX on "Practical Considerations for Development and Application of a Toolkit...
Meta-analyses have been increasingly used in the scientific evaluation of efficacy and safety in benefit-risk assessments, as well as for pricing and the reimbursement of biopharmaceutical products. Over the last few years, the outcome of meta-analyses has been both debated and used as evidence within the regulatory process for human medicinal products, and their interpretation has ometimes contributed to different regulatory actions for the same product.
Read more: CIOMS Working Group X on "Considerations for applying good meta-analysis practices to clinical...
Historically, the project began in 2003 as a CIOMS initiative, in response to indications received from some drug regulatory authorities and pharmaceutical companies that they had concerns about the parallel development of special drug safety search programs based on the Medical Dictionary for Regulatory Activities (MedDRA). This would cause an unavoidable duplication of effort and uncertainty within pharmaceutical companies about the utility of these searches on the part of drug regulatory authorities.
Read more: CIOMS Working Group on Standardised MedDRA Queries (SMQs)
The report is an updated and extended version of a recent publication in Basic and Clinical Ph...
3rd Vaccine Safety Working Group, CDC, Atlanta, GA, USA, 5-6 February 20147th Working Group X on Meta-analysis, Durham, North Carolina, USA, 25-26 February 20145th Working Group on Revision of CIOMS International Ethical Guidelines, Utrecht, Netherlands, 26-28 February 20145th Working Group on MedDRA, ICH, Geneva, Switzerland, 9-10 April 20146th Working Group on Revision of CIOMS International Ethical Guidelines, Geneva, Switzerland, 21-23 May 2014
CIOMS 80th Executive Committee Meeting, XXI General Assembly & Workshop, 20 November 2013, WHO Headquarters, Geneva, Switzerland
CIOMS 4th Working Group on Revision of CIOMS International Ethical Guidelines, 17-19 November 2013, WHO Headquarters, Geneva, SwitzerlandCIOMS Working Group on Vaccine Safety 17-18 September 2013 , WHO Headquarters, Geneva, Switzerland
CIOMS WG X on Considerations for applying good meta-analysis practices to clinical safety data within the biopharmaceutical regulatory process, 12-13 September 2013, Singapore
CIOMS Working Group on the Review of 2002 International Ethical Guidelines, 26-28 June 2013, UMC, Utrecht, The Netherlands
CIOMS WG on Vaccine Safety, 29-30 May 2013 , EMA, London, UK
CIOMS Working Group on the Review of 2002 International Ethical Guidelines, 11-12 February 2013, Geneva, Switzerland
CIOMS Working Group X, 14-15 March 2013, MEB, Utrecht, The Netherlands
CIOMS Working Group IX, 18-19 March 2013, NDA, Stockholm, Sweden
MedDRA 3rd IWG Meeting, 9-10 April 2013, IFPMA/CIOMS, Geneva, Switzerland
© 2013 CIOMS - All rights reserved